In normal tissues with low EGFR expression, nimotuzumab binding interaction is transient, thus avoiding severe dose-limiting toxicity. However, both antibodies revealed similar tumor growth inhibiting in tumor tissue with high EGFR expression (44). This evidence concerns the gene EGFR and neoplasm.